Richmond Pharmacology presents �Improving Clinical Trial Design�at the BAPU 4th 2-yearly Symposium 2012

The Belgian Association of Phase 1 Units (BAPU) will host its 4th 2-yearly symposium this year in Antwerp, taking place 9th November 2012. The focus of this year�s meeting is modernising and innovation in early clinical drug development towards 2020.Founded in January 2005, BAPU represents the Belgian phase I clinical research units from both the pharmaceutical industry and academia. One of its primary objectives is to facilitate collaboration between Belgian phase I units as well as international phase I units and regulatory authorities.Invited on behalf of BAPU, Dr Ulrike Lorch�s presentation on Improving Clinical Trial Design will describe the benefit of adaptive design in First into Human and Early Phase Combination Studies, showing how its use, compared to conventional study designs, can lead to comprehensive time savings in early research programs.Click here to view full program and to registerWatch our latest presentation on Adaptive Study Design

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event